Glutamate receptor dysfunction and schizophrenia

Archives of General Psychiatry

Volumn 52, Issue 12, 1995, Pages 998-1007

  Olney, John W ^a   Farber, Nuri B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPERLAPINE; GLUTAMATE RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE;

AGING; BINDING AFFINITY; BRAIN INJURY; CLINICAL FEATURE; HUMAN; HYPOTHESIS; NARCOLEPSY; NERVE DEGENERATION; REVIEW; SCHIZOPHRENIA;

EID: 0028850552     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1995.03950240016004     Document Type: Review

References (120)

1. Kendler KS, Diehl SR. The genetics of schizophrenia: a current genetic-epidemiologic perspective. Schizophr Bull. 1993;19:261-285.
2. Stabenau JR, Pollin W, Heredity and environment in schizophrenia, revisited: the contribution of twin and high-risk studies. J Nerv Ment Dis. 1993;181:290-297.
3. Stevens JR. An anatomy of schizophrenia? Arch Gen Psychiatry. 1973;29:177-189.
4. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2:924-926.
5. Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry. 1979;36:735-739.
6. Scheibel AB, Kovelman JA. Disorientation of the hippocampal pyramidal cell and its processes in the schizophrenic patient. Biol Psychiatry. 1981;16:101-102.
7. Bogerts B, Meertz E, Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volume and shrinkage. Arch Gen Psychiatry. 1985; 42:784-791.
8. Brown R, Colter N, Corsellis JAN, Crow TJ, Frith CD, Jagoe R, Johnstone EC, Marsh L. Post-mortem evidence for structural brain changes in schizophrenia: differences in brain weight, temporal horn area and parahippocampal gyrus width as compared with affective disorder. Arch Gen Psychiatry. 1986;43:36-42.
9. Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci. 1986;236:154-161.
10. Falkai P, Bogerts B, Rozumek M. Limbic pathology in schizophrenia: the entorhinal region - a morphometric study. Biol Psychiatry. 1988;24:515-521.
11. Jeste D, Lohr JB. Hippocampal pathologic findings in schizophrenia. Arch Gen Psychiatry. 1989; 46:1019-1024.
12. Benes FM, McSparren J, San-Giovanni JP, Vincent SL. Deficits in small interneurons in cingulate cortex of schizophrenic and schizoaffective patients. Arch Gen Psychiatry. 1991;48: 996-1001.
13. Stevens JR. Abnormal reinnervation as a basis for schizophrenia: a hypothesis. Arch Gen Psychiatry. 1992;49:238-243.
14. Shenton ME, Kikinis R, Jolesz FA, Pollak, SD, LeMay M, Wible CG, Hokama H, Martin J, Metcalf D, Coleman M, McCarley RW. Abnormalities of the left temporal lobe and thought disorder in schizophrenia: a quantitative magnetic resonance imaging study. N Engl J Med. 1992;327:604-612.
15. Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophr Bull. 1993; 19:431-445.
16. Kovelman JA, Scheibel AB. A neurohistological correlate of schizophrenia. Biol Psychiatry. 1984;191:1601-1621.
17. Jakob H, Beckman H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm. 1986;65:303-326.
18. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? BMJ. 1987;95:681-682.
19. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660-669.
20. Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry. 1988;45;189-192.
21. Benes FM. Myelination of cortical-hippocampal relays during late adolescence. Schizophr Bull. 1989;15:585-593.
22. DeLisi LE. The significance of age of onset for schizophrenia. Schizophr Bull. 1992;18:209-215.
23. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325-351.
24. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149: 1183-1188.
25. Carlsson A. Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry. 1978;135:165-173.
26. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1988;1:179-186.
27. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenia patients and a new hypothesis on schizophrenia. Neurosci Lett. 1980; 20:379-382.
28. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett. 1982;28:81-85.
29. Olney JW. Endogenous excitotoxins and neuropathological disorders. In: Lodge D, ed. Excitatory Amino Acids in Health and Disease. Chichester, England: John Wiley & Sons Ltd; 1988:337-351.
30. Olney JW. Excitatory transmitters and neuropsychiatric disorders. In: Ferrendelli JA, Collins RC, Johnson EM, eds. Neurobiology of Amino Acids, Peptides, and Trophic Factors. Boston, Mass: Kluwer Academic Publishers; 1988: 51-61.
31. Olney JW. Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry. 1989;26: 505-525.
32. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A 'glutamatergic hypothesis' of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol. 1989; 12:1-13.
33. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull. 1990;16:425-432.
34. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
35. Lodge D, Anis NA. Effects of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat. Eur J Pharmacol. 1982; 77:203-204.
36. Lodge D, Aram JA, Church J, Davies SN, Martin D, O'Shaughnessy CT, Zeman S. Excitatory amino acids and phencyclidine-like drugs. In: Hicks TP, Lodge D, McLennan H, eds. Excitatory Amino Acid Transmission. New York, NY: Alan R Liss Inc; 1987:83-90.
37. Kristensen JD, Svensson B, Gordh T. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain. 1992;51:249-253.
38. Herrling PL. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist: results from animal models and first results in humans. Neuropsychopharmacology. 1994;10(No. 3S):591S.
39. Grotta J. Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke. 1994;25:255.
40. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug-Sernyl. Arch Neurol Psychiatry. 1959;81:363-369.
41. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D. Comparison of Sernyl with other drugs: simulation of schizophrenic performance with Sernyl, LSD-25, and amobarbital (Amytal), I: attention, motor function, and proprioception. Arch Gen Psychiatry. 1959;1: 651-656.
42. Davies BM, Beech HL. The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J Ment Sci. 1960;106:912-924.
43. Bakker C, Amini F. Observations on the psychotomimetic effects of Sernyl. Compr Psychiatry. 1961;2:269-280.
44. Ban TA, Lohrenz JJ, Lehmann HE. Observations on the action of Sernyl - a new psychotropic drug. Can Psychiatr Assoc J. 1961;6: 150-157.
45. Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs: simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium, II: symbolic and sequential thinking. Arch Gen Psychiatry. 1962;6:395-401.
46. Luisada PV, Brown BL. Clinical management of phencyclidine psychosis. Clin Toxicol. 1976;9: 539-545.
47. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry. 1978;135:1081-1084.
48. Erard R, Luisada PV, Peele R. The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? J Psychedelic Drugs. 1980;12:235-245.
49. Reich DL, Silvay G. Ketamine: an update on the first twenty years of clinical experience. Can J Anaesth. 1989;36:186-197.
50. White PF, Way WL, Trevor AJ. Ketamine - its pharmacology and therapeutic uses. Anesthesiology. 1982;56:119-136.
51. Korttila K, Levanen J. Untoward effects of ketamine combined with diazepam for supplementing conduction anaesthesia in young and middle-aged adults. Acta Anaesthesiol Scand. 1978;22:640-648.
52. Magbagbeola JAO, Thomas NA. Effect of thiopentone on emergence reactions to ketamine anaesthesia. Can J Anaesth. 1974;21:321-324.
53. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF. Model psychoses and schizophrenia. Am J Psychiatry. 1962;119:61-67.
54. Garey RE. PCP (phencyclidine): an update. J Psychedelic Drugs. 1979;11:265-275.
55. Domino E, Luby E. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino E, ed. PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor, Mich: NPP Books; 1981:401-418.
56. Krystal JH, Karper LP, Seibyl JP, Delaney R, Bremner JD, Bowers MB, Charney DS. Dose-related effects of the NMDA antagonist, ketamine, in healthy humans. Schizophr Res. 1993; 9:240-241.
57. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
58. Lahti AC, LaPorte DJ, Mokriski B, Tamminga CA. Effects of the NMDA antagonist ketamine in schizophrenic patients. Soc Neurosci Abstr. 1993;19:1351.
59. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989; 244:1360-1362.
60. Olney JW, Labruyere J, Wang G, Sesma MA, Wozniak DF, Price MT. NMDA antagonist neurotoxicity: mechanism and protection. Sci-ence. 1991;254:1515-1518.
61. Hargreaves RJ, Rigby M, Smith D, Hill RG, Iversen LL. Competitive as well as uncompetitive NMDA receptor antagonists affect cortical v neuronal morphology and cerebral glucose metabolism. Neurochem Res. 1993;18:1263-1269.
62. Sharp FR, Jasper P, Hall J, Noble L, Sagar SM. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol. 1991; 30:801-809.
63. Sharp FR, Butman M, Aardalen K, Nakki R, Koistinaho J, Massa S, Sagar SM. Phencyclidine induces the HSP70 heat shock gene in injured cortical neurons via multiple receptors: disinhibition as a mechanism of injury. Soc Neurosci Abstr. 1993;19:1697.
64. Allen HL, Iversen LL. Phencyclidine, dizocilpine and cerebrocortical neurons. Science. 1990; 247:221.
65. Fix AS, Horn JW, Wightman KA, Johnson CA, Long GC, Storts RW, Farber NB, Wozniak DF, Olney JW. Neuronal vacuolization and necrosis induced by the noncompetitive M-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol. 1993;123:204-215.
66. Fix AS, Wozniak DF, Truex LL, McEwen M, Miller JP, Olney JW. Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Res. In press.
67. Wozniak DF, McEwen M, Sesma MA, Olney JW, Fix AS. MK-801 induces extensive neuronal necrosis in posterior cingulate/retrosplenial cortices. Soc Neurosci Abstr. 1993;19:1770.
68. Corso TD, Wozniak DF, Sesma MA, Olney JW. Neuron necrotizing properties of phencyclidine. Soc Neurosci Abstr. 1994;20:1531.
69. Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa SM, Swanson RA, Sagar SM. Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience. 1994;62:1079-1092.
70. Corso T, Neafsey EL, Collins M. Ethanol-induced degeneration of dentate gyrus, entorhinal cortex and other olfactory related areas in rat: effects of co-administration of MK-801, DNQX, or nimodipine. Soc Neurosci Abstr. 1992; 18:540.
71. Horvath Z, Buzsaki G. MK-801-induced neuronal damage in normal rats. Soc Neurosci Abstr. 1993;19:354.
72. Ellison G, Switzer RC. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport. 1993;5:17-20.
73. Ellison G. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport. 1994;5:2688-2692.
74. Olney JW, Sesma MA, Wozniak DF. Glutamatergic, cholinergic, and GABAergic systems in posterior cingulate cortex: interactions and possible mechanisms of limbic system disease. In: Vogt BA, Gabriel M, eds. Neurobiology of Cingulate Cortex and Limbic Thalamus. Boston, Mass: Birkhäuser; 1993:557-580.
75. Olney JW, Farber NB. Efficacy of clozapine compared to other antipsychotics in preventing NMDA antagonist neurotoxicity. J Clin Psychiatry. 1994; 55(suppl B):9.
76. Farber NB, Price MT, Labruyere J, Nemnich J, St Peter H, Wozniak DF, Olney JW. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry. 1993; 34:119-121.
77. Farber NB, Price MT, Labruyere J, Nemnich J, St Peter H, Olney JW. Protection against NMDA antagonist neurotoxicity by clozapine and related analogs correlates with antipsychotic efficacy. Soc Neurosci Abstr. 1993;19:384.
78. Farber NB, Foster J, Olney JW. Clozapine and related analogs block NMDA antagonist neurotoxicity: implications for schizophrenia. Schizophr Res. 1995;15:57-58.
79. 2-Adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology. 1995;12:347-349.
80. Sharp FR, Butman M, Wang S, Koistinaho J, Graham SH, Sagar SM, Noble L, Berger P, Longo FM. Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK-801, and ketamine. J Neurosci Res. 1992;33:605-616.
81. Price MT, Farber NB, Labruyere J, Foster J, Olney JW. Tracing the circuitry that mediates NMDA antagonist neurotoxicity. Soc Neurosci Abstr. 1994;20:1532.
82. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 1992;260:576-580.
83. Monnet FP, Debonnel G, Junien JL, De Montigny C. M-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptors. Eur J Pharmacol. 1990;179:441-445.
84. 3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther. 1992;261:123-130.
85. Gue M, Junien JL, Del Rion C, Bueno L. Neuropeptide Y and sigma ligand (JO 1784) suppress stress-induced colonie motor disturbances in rats through sigma and cholecystokinin receptors. J Pharmacol Exp Ther. 1992;261: 850-855.
86. Riviere PJM, Pascaud X, Junien JL, Porreca F. Neuropeptide Y and JO 1784, a selective sigma ligand, alter intestinal ion transport through a common, haloperidol-sensitive site. Eur J Pharmacol. 1990;187:557-559.
87. Farber NB, Price MT, Labruyere J, Fuller TA, Olney JW, Age dependency of NMDA antagonist neurotoxicity. Soc Neurosci Abstr. 1992; 18:1148.
88. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H, Olney JW. Age specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry. In press.
89. Marshall BE, Longnecker DE. General anesthetics. In: Goodman LS, Gilman A, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. Elmsford, NY: Pergamon Press Ilnc; 1990:285-310.
90. Karp HN, Kaufman ND, Anand SK. Phencyclidine poisoning in young children. J Pediatr. 1980; 97:1006-1009.
91. Welch MJ, Correa GA. PCP intoxication in young children and infants. Clin Pediatr (Phila). 1980; 19:511-514.
92. McDonald JW, Silverstein FS, Johnston MV. Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system. Brain Res. 1988;459:200-203.
93. Ikonomidou C, Price MT, Mosinger JL, Frierdich G, Labruyere J, Shahid Salles K, Olney JW. Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain. J Neurosci. 1989;9:1693-1700.
94. Ikonomidou C, Mosinger JL, Shahid Salles K, Labruyere J, Olney JW. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J Neurosci. 1989;9:2809-2818.
95. Andersson T, Schwarcz R, Löve A, Kristensson K. Measles virus-induced hippocampal neurodegeneration in the mouse: a novel, subacute model for testing neuroprotective agents. Neurosci Lett. 1993;154:109-112.
96. Benes FM, Davidson J, Bird ED. Quantatative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry. 1986; 43:31-35.
97. Bogerts B, Falkai P, Tutsch J. Cell numbers in the pallidum and hippocampus of schizophrenics. In: Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM, eds. Biological Psychiatry. Amsterdam, the Netherlands: Elsevier Science Publishers; 1986,7:1178-1180.
98. Fix AS, Wightman KA, O'Callaghan JP. Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunocyto-chemistry. Neurotoxicology. 1995;16:229-239.
99. Andreasen NC, Arndt S, Swayze V, Cizadlo T, Flaum M, O'Leary D, Ehrhardt JC, Yuh WTC. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science. 1994;266:294-298.
100. Schwarcz R, Creese I, Coyle JT, Snyder SH. Dopamine receptors localized on cerebral cortical afferents to rat corpus striatum. Nature. 1978; 271:766-768.
101. Rowlands GC, Roberts PJ. Activation of dopamine receptors inhibits calcium-dependent glutamate release from cortico-striatal terminals in vitro. Eur J Pharmacol. 1980;62:241-247.
102. Kornhuber J, Kornhuber ME. Presynaptic dopaminergic modulation of cortical input to the striatum. Life Sci. 1986;39:699-774.
103. Maura G, Giardi A, Raiteri M. Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. J Pharmacol Exp Ther. 1988;247:680-684.
104. Maura G, Carbone R, Raiteri M. Aspartate-releasing nerve terminals in rat striatum possess D-2 dopamine receptors mediating inhibition of release. J Pharmacol Exp Ther. 1989;251:1142-1146.
105. Maura G, Barzizza A, Lottero P, Raiteri M. The excitatory amino acid-releasing nerve terminals in rat striatum possess D-2 dopamine receptors mediating inhibition of release. Neurochem Int. 1990;16(suppl 1):53.
106. Weinberger DR, Bigelow LB, Kleinman JE, Klein ST, Rosenblat JE, Wyatt RJ. Cerebral ventricular enlargement in chronic schizophrenia: an association with poor response to treatment. Arch Gen Psychiatry. 1980;37:11-13.
107. Andreasen NC, Olsen SA, Dennert JW, Smith MR. Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am J Psychiatry. 1982;139:297-302.
108. Pearlson GD, Garbacz DJ, Breakey WR, Ahn HS, DePaulo JR. Lateral ventricular enlargement associated with persistent unemployment and negative symptoms in both schizophrenia and bipolar disorder. Psychiatry Res. 1984;12:1-9.
109. Pogue-Geille MF, Harrow M. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr Bull. 1985; 11:427-439.
110. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
111. Meltzer HY. Clozapine: pattern of efficacy in treatment-resistant schizophrenia. In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York, NY: Raven Press; 1992:33-46.
112. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994;151:1234-1236.
113. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry. 1991;148:714-726.
114. Hollister LE, Müller-Oerlinghausen B, Rickels K, Shader RI. Clinical use of benzodiazepines. J Clin Psychopharmacol. 1993;13(suppl 1):1S-169S.
115. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. Arch Gen Psychiatry. 1989;46:745-753.
116. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson J. Muscarinic Cholinergic hyperactivity in schizophrenia: relationship to positive and negative symptoms. Schizophr Res. 1991;4:23-30.
117. Fayen M, Goldman MB, Moulthrop MA, Luchins DJ. Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. Am J Psychiatry. 1988;145:483-486.
118. Tandon R, Greden JF, Silk KR. Treatment of negative schizophrenic symptoms with trihexiphenidyl. J Clin Psychopharmacol. 1988;8:212-215.
119. Fisch RJ. Trihexiphenidyl abuse: therapeutic implications for negative symptoms of schizophrenia. Acta Psychiatr Scand. 1987;75:91-94.
120. Wells BG, Marken PA, Richman LA, Brown CS, Hamann G, Grimmig J. Characterizing anticholinergic abuse in community mental health. J Clin Psychopharmacol. 1989;9:431-435.